Industry landscapes
The companies, capital and talent shaping life sciences in Australia. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
30 of 901 tracked companies have open roles.
213 of 901 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 367 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 33.4% of disclosed capital, while 76.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $178.19M | 42 | 26 |
| 2017 | $240.41M | 48 | 29 |
| 2018 | $275.66M | 61 | 28 |
| 2019 | $201.87M | 44 | 32 |
| 2020 | $408.85M | 49 | 37 |
| 2021 | $726.97M | 29 | 35 |
| 2022 | $1.17B | 16 | 39 |
| 2023 | $156.59M | 14 | 17 |
| 2024 | $434.2M | 4 | 27 |
| 2025 | $858.94M | 5 | 31 |
Share of all disclosed company funding.
412 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by .
Backed by .
Backed by SV Health Investors and Sanofi Ventures and others.
Backed by TDM Growth Partners.
Backed by GrowthWorks Capital and BDC and others.
Backed by SGH and Cochlear and others.
Backed by SPRIM Global Investments and LGT Crestone and others.
Backed by Northpond Ventures and Platinum and others.
Backed by National Reconstruction Fund and Brandon Capital.
Participating investors were not recorded in this snapshot.
Backed by One Ventures and Acorn Capital.
Backed by Uniseed and Minderoo Foundation and others.
The measured Australia identity-to-filing probe did not produce a qualifying designated legal or national-ID join: bare ticker overlaps lack a recorded ASX exchange designation and are not designated legal or national identifiers.; The measured Australia identity-to-filing probe did not produce a qualifying designated legal or national-ID join: bare ticker overlaps lack a recorded ASX exchange designation and are not designated legal or national identifiers.
How the Australia companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
20 of these companies (2.2%) publish at least one Android app — 32 apps in all, carrying 171K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Bladder Diary by iUFlowiUFlow mHealth | 72.8K | 4.8 | Medical |
| SomfitCompumedics | 31.2K | 3.7 | Health & Fitness |
| ReactDx SleepReactDx | 17.8K | 3.7 | Health & Fitness |
| DermapenworldDermapen World | 14.1K | — | Beauty |
| OrivetOrivet | 12.5K | 2.9 | Shopping |
| LifeSmart Sugar CheqLifeSmart | 5.4K | — | Health & Fitness |
| PeriCoachPeriCoach | 4.7K | — | Medical |
| WelleCo UKWelle Co | 2.7K | — | Shopping |
| LifeSmart HealthLifeSmart | 2.3K | — | Health & Fitness |
| WelleCo USWelleCo | 2.3K | 4.8 | Shopping |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q2–2025Q4).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Wearable Technology | 8 | 99.4K | Bladder Diary by iUFlow 72.8K | |
| Healthcare It | 8 | 93.2K | ReactDx Sleep 17.8K | |
| Disease Self Management | 8 | 86.3K | LifeSmart Sugar Cheq 5.4K | |
| Neurology | 3 | 31.3K | Somfit 31.2K | |
| Sleep Medicine | 2 | 31.2K | CMP Research Somfit V1 17 | |
| Cardiac And Vascular Disorders | 2 | 18K | SpiroSonic 186 | |
| Dermatology | 4 | 14.6K | Dermapenworld 14.1K | |
| Genomics | 4 | 12.7K | Orivet 12.5K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 23 of 32 apps carry a release date. The series ends at 2025Q4, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
27 companies hiring · $4.53B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Cynata Therapeutics has secured firm commitments to raise $1.5 million through an institutional placement as it awaits Phase 3 osteoarthritis trial results this month.
Syntara Limited (ASX:SNT) has secured firm commitments for an A$8.0 million two-tranche institutional placement and plans to launch a non-underwritten share purchase plan targeting around A$2.0 million.
Radoff and Torok, who with certain of their affiliates comprise the Radoff-JEC Group, are now offering $2.35 per share plus a contingent value right.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly‑owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc.
Roquefort has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Cann Group has secured $750,000 in funding through a convertible securities agreement with US-based investor Obsidian Global.
Perth-based medtech innovator OncoRes Medical has secured $27 million in private funding, which will help progress clinical trials in breast cancer surgery using its world-class precision imaging technology.
Propanc Biopharma had issued 1,000,000 shares in its initial public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00.
drawing down US$75 million from a new five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George.
Singapore-based, state-owned investors GIC and Temasek acquired a stake in Novotech with prior owner TPG reinvesting in the CRO.
Top 10 categories among 480 recorded events in the 24-month window.
20 companies with recorded IPO activity
IPO · OTCMKTS5 reports
IPO · ASX3 reports
OFS · NASDAQ2 reports
IPO · ASX2 reports
IPO · ASX7 reports
IPO · ASX5 reports
IPO1 reports
IPO · Nasdaq2 reports
28 tracked people moves
Departure Previously Board Member
Appointment Board Member
Appointment Board Member
Appointment Non-Executive Director
Appointment Non-Executive Director
Appointment Non-Executive Director
Appointment Chief Product Officer
Appointment Independent Non-Executive Director
Products, platforms and features in the recorded window
Medical device
15 recorded customer wins
Customer: regeneron pharmaceuticalsBiopharmaceutical
Customer: Advance Realty Investors and Greek Real Estate Partners (GREP)Logistics
Customer: imv technologiesAnimal reproduction
Customer: imv
Customer: cancer care associatesHealthcare
Customer: sandozPharmaceutical
2 companies with reported reductions
39 rolesstudy discontinuation
50.0% rolescost reduction
21 recorded events
approved for saleU.S.
application accepted for approvalNational Health Authority (NMPA)
approval for investmentChina ODI
first FDA-approved mesenchymal stromal cell (MSC) therapyU.S. Food & Drug Administration (FDA)
6 tracked suits
breach of fiduciary duties over tax benefit planCivil · Ongoing
Federal Securities Laws violationCivil · Filed
Reported company results in the recorded window.
Median across 72 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Radoff-JEC Group→Seer ↗ | Announced | 2026-04-24 | Not stated in snapshot |
| xortx therapeutics→Vectus Biosystems ↗ | Announced | 2026-04-02 | Not stated in snapshot |
| roquefort therapeutics→Lyramid ↗ | 2026-03-28 | Not stated in snapshot | |
| GIC & Temasek→Novotech ↗ | 2025-12-22 | Not stated in snapshot | |
| LTR Pharma→LevOmega | Announced | 2025-09-22 | Not stated in snapshot |
| richards→Dermapen World ↗ | 2025-07-16 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
Recorded hiring and workforce signals from the available source snapshot.
No repeated job title is supported by this snapshot.
0 tracked postings mention remote work.
| Company | Employees |
|---|---|
| Seer ↗ | 328 |
| Telix Pharma ↗ | 234 |
| SpeeDx ↗ | 113 |
| Vaxxas ↗ | 113 |
| Pharmaxis ↗ | 93 |
| CurveBeam AI ↗ | 83 |
| Mesoblast ↗ | 83 |
| Cann Group ↗ | 79 |
538 founders and chief executives across 432 companies.
Ex-Princess Alexandra & Wesley Hospitals. The University of Queensland BSc
Ex-CEO Merck, Director US-ASEAN Business Council, Board Of Directors The Association Of The British Pharmaceutical Industry…
CGI Glass Lewis, G2 Therapies, ex-Yuan Chuan Radio Advertising, Equity Partners Asia, Zurich Centre Group. University of California Berkeley BA 1997
University of North Carolina at Greensboro BS 1995
LENZ Therapeutics, ex-Novartis, Alcon, Novartis, Medicines Australia, Servier. University of Rouen PhD 1995, HEC Paris 1996
Ex-CSIRO. The University of Western Australia BSc 1981, PhD 1986
Ex-Acrux, ANZ Banking Group, Celltech, Medeva. The University of Reading BSc 1998
Speedx, ex-Industry Mentoring Network In Stem, ex-Springboard Enterprises, UNSW, 2007
Founder Cytochroma_uk, ex-Science Squared. The University of Edinburgh BSc 2007
Ex-Novartis Pharmaceuticals Australia, Novartis Asia Pacific, Ciba Pharmaceuticals. University of Nottingham 1981, Henley Business School MBA 1992
Ex-Medical Enzymes, Deutsche Life Science, NET.IPO AKTIENGESELLSCHAFT, Allianz.
ex-Medical Device Manufacturers Association, President Boston Scientific. D'Amore-McKim School of Business 1998
51 profiles with education records.
3 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
639,765 articles in the measured 12-month window.
Life Sciences coverage across Australia · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 103,166 |
| 2021Q3 | 118,628 |
| 2021Q4 | 102,971 |
| 2022Q1 | 117,890 |
| 2022Q2 | 111,616 |
| 2022Q3 | 119,347 |
| 2022Q4 | 176,633 |
| 2023Q1 | 199,589 |
| 2023Q2 | 127,914 |
| 2023Q3 | 150,747 |
| 2023Q4 | 136,683 |
| 2024Q1 | 130,725 |
| 2024Q2 | 142,750 |
| 2024Q3 | 142,715 |
| 2024Q4 | 155,881 |
| 2025Q1 | 184,871 |
| 2025Q2 | 118,496 |
| 2025Q3 | 221,521 |
| 2025Q4 | 106,134 |
| 2026Q1 | 122,638 |
Article volume measures coverage, not market sales.
631 recorded company events across 107 companies; percentages use that event total.
Life Sciences coverage across Australia · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Australia
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,005 | 1,939 | 107% |
| domestic robots | 3,101 | 38 | 8061% |
| toy robots | 3,081 | 25 | 12224% |
| ashes moments | 1,190 | 772 | 54% |
| angel investors | 1,016 | 369 | 175% |
| overseas study | 971 | 686 | 42% |
| ashes urn | 896 | 392 | 129% |
| ashes records | 856 | 403 | 112% |
| semester abroad | 816 | 522 | 56% |
| ashes venues | 808 | 429 | 88% |
| test cricket | 5,970 | 11,551 | -48% |
| test innings | 4,542 | 8,868 | -49% |
| 5-day cricket | 3,718 | 7,768 | -52% |
| odi cricket | 2,922 | 6,170 | -53% |
| limited overs cricket | 2,793 | 6,145 | -55% |
Life Sciences coverage across Australia
territories, disputed islands, test cricket
27.3% critical · 18.7% positivetest cricket, test innings, odi world cup
31.5% critical · 42.1% positivecore inflation rate, inflation outlook, aflw premiership
31.9% critical · 46.5% positiveLife Sciences coverage across Australia. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Researchers discuss challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Papers highlight microbial hazards and nutritional impacts linked to food manufacturing and consumer health.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Studies examine hurdles in controlling gene activity and mRNA applications across cell and animal models.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Research points to difficulties in improving plant nutrient uptake and breeding for resilient, high‑yield crops.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Works address obstacles in pest control, host resistance, and integrated strategies for protecting crops.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Articles discuss the spread of drug‑resistant microbes in humans, animals, and the environment.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Papers cover a range of unrelated topics from molecular order to interdisciplinary analyses.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Studies warn about oxidative stress and viability impacts when testing substances in vitro and in vivo.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Research cautions on the limits of breeding predictions and the need for robust validation.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Papers advise careful evaluation of novel feed compounds for sustainability and animal welfare.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Works highlight potential hazards in food additives and the importance of thorough safety assessments.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Research underscores complexities in genomic stability and the need for precise diagnostic tools.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Studies point out unintended resistance development when antibiotics are combined with other agents.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Articles discuss the challenges of evolving pest resistance and the need for adaptive dosing strategies.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Papers explore novel antibody formats and fluorescence methods for improved in vivo analysis.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Research highlights potential of gene knockdown and modulation to treat disease and control cell growth.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Studies present emerging plant‑based ingredients that support nutrition and antioxidant activity.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Works focus on DNA methylation tools and sensitive assays for disease‑related molecular signals.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Research investigates plant‑derived compounds and postbiotic products as new strategies against pathogens.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Papers examine trait mapping and selection methods to boost productivity in staple grains.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Studies highlight microbial fermentation and by‑product valorization for greener agriculture and energy.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.6% |
| Promising | 30.4% | 36.8% |
| Breakthrough | 14.1% | 26.8% |
| Problem-identifying | 8.3% | 9.4% |
| Cautionary | 3.5% | 4.5% |
| Comparative | 2.4% | 3.9% |
| Critical | 1.0% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Compare demand signals in Australia’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Maternal & child health ↗Disease Burden | 62.5 | 16.7 | +45.8 | +62.8% | |
| Layoffs & income shocks ↗Spending Pressure | 87.5 | 66.7 | +20.8 | +94.9% | |
| Ageing & elder care ↗Disease Burden | 0.0 | 16.7 | -16.7 | +2.2% | |
| Cancer burden ↗Disease Burden | 37.5 | 100.0 | -62.5 | +38.0% | |
| Mental health ↗Disease Burden | 62.5 | — | No matching category | — | +26.6% |
Showing all 5 signals. Select a family for its history and mapped categories.
All 8 city readings for these demand families in the comparison geography. Australia is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Mental health · Ageing & elder care
Maternal & child health · Ageing & elder care · Mental health
Mental health · Layoffs & income shocks · Maternal & child health
Mental health · Maternal & child health · Ageing & elder care
Maternal & child health · Cancer burden · Mental health
Mental health · Layoffs & income shocks · Maternal & child health
Cancer burden · Mental health · Maternal & child health
Mental health · Layoffs & income shocks · Maternal & child health
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 85 | 12.61 |
| 2024Q4 | 70 | 8.9 |
| 2025Q1 | 89 | 11.27 |
| 2025Q2 | 86 | 14.73 |
| 2025Q3 | 168 | 20.42 |
| 2025Q4 | 71 | 12.35 |
| 2026Q1 | 63 | 10.38 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 88 | 13.05 |
| 2024Q4 | 101 | 12.84 |
| 2025Q1 | 96 | 12.15 |
| 2025Q2 | 61 | 10.45 |
| 2025Q3 | 215 | 26.14 |
| 2025Q4 | 105 | 18.27 |
| 2026Q1 | 154 | 25.37 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 82 | 12.16 |
| 2024Q4 | 137 | 17.42 |
| 2025Q1 | 79 | 10.0 |
| 2025Q2 | 91 | 15.59 |
| 2025Q3 | 112 | 13.62 |
| 2025Q4 | 61 | 10.61 |
| 2026Q1 | 60 | 9.89 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 73 | 10.83 |
| 2024Q4 | 86 | 10.93 |
| 2025Q1 | 75 | 9.49 |
| 2025Q2 | 63 | 10.79 |
| 2025Q3 | 129 | 15.68 |
| 2025Q4 | 73 | 12.7 |
| 2026Q1 | 72 | 11.86 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 126 | 18.69 |
| 2024Q4 | 282 | 35.85 |
| 2025Q1 | 87 | 11.01 |
| 2025Q2 | 94 | 16.1 |
| 2025Q3 | 142 | 17.26 |
| 2025Q4 | 294 | 51.15 |
| 2026Q1 | 129 | 21.25 |
Australia life sciences coverage
Australian & New Zealand Journal of Psychiatry
557 citations in the snapshot
Clinical Infectious Diseases
472 citations in the snapshot
The Medical Journal of Australia
439 citations in the snapshot
Scientific Reports
389 citations in the snapshot
Australia coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| school-entry vaccine requirements | 82 | 29 | 224.9% |
| elderly vaccination guidelines | 83 | 35 | 172.5% |
| childhood immunization laws | 84 | 36 | 168.1% |
| healthy diet cancer | 53 | 24 | 153.7% |
| pediatric catch-up vaccinations | 93 | 52 | 105.5% |
| online safety parenting | 73 | 129 | -35.0% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
33.9% across the displayed hubs
6 companies hiring · $1.7B disclosed funding
Explore companies in Melbourne ↗
31.3% across the displayed hubs
5 companies hiring · $1.8B disclosed funding
Explore companies in Sydney ↗
14.4% across the displayed hubs
4 companies hiring · $780.6M disclosed funding
Explore companies in Brisbane ↗
8.0% across the displayed hubs
2 companies hiring · $152.3M disclosed funding
Explore companies in Perth ↗
5.8% across the displayed hubs
0 companies hiring · $109.2M disclosed funding
Explore companies in Adelaide ↗2.2% across the displayed hubs
1 companies hiring · $65.7M disclosed funding
Explore companies in Notting Hill ↗
2.2% across the displayed hubs
0 companies hiring · $32.3M disclosed funding
Explore companies in Nedlands ↗
2.2% across the displayed hubs
1 companies hiring · $23.8M disclosed funding
Explore companies in Canberra ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗